CRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CorMedix Inc (CRMD) is not a good buy for a beginner investor with a long-term focus at this time. Despite strong revenue growth, significant challenges such as missed earnings expectations, bearish technical indicators, and reduced analyst price targets suggest caution. The stock's recent sharp decline and lack of strong positive catalysts make it unsuitable for immediate investment.
The technical indicators are bearish. The MACD is slightly positive but contracting, RSI is neutral at 22.929, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 6.371 and S2 at 6.062. The overall trend suggests weakness.
CorMedix reported Q4 2025 revenue of $128.6 million, a 312% YoY increase, and approved a $75 million share buyback plan. The company also maintains strong sales of DefenCath and the Melinta portfolio.
Q4 2025 earnings per share of $0.16 missed market expectations by $0.66, leading to a ~12% drop in stock price. Analysts have lowered price targets significantly, citing reduced FY26 and FY27 revenue guidance. Operating expenses have risen sharply, and the stock has experienced a significant pre-market and regular market decline.
CorMedix's Q4 2025 revenue surged 312% YoY to $128.6 million, but net income and EPS missed expectations. Operating expenses increased significantly, and the company has faced challenges in maintaining profitability despite revenue growth.
Analysts have lowered price targets significantly, with H.C. Wainwright, RBC Capital, and Truist reducing their targets to $13-$16 from higher levels. Analysts maintain Buy or Outperform ratings but highlight concerns around reduced revenue guidance and the need for clinical execution.
